# Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder

> **NCT06588010** · PHASE3 · RECRUITING · sponsor: **Centre Hospitalier Universitaire Dijon** · enrollment: 110 (estimated)

## Conditions studied

- Neurogenic Bladder

## Interventions

- **DRUG:** OM-89 [Uro-Vaxom® Capsule]
- **DRUG:** OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo]

## Key facts

- **NCT ID:** NCT06588010
- **Lead sponsor:** Centre Hospitalier Universitaire Dijon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06588010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06588010, "Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06588010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*